12 August 2022 - The past 30 years have seen a considerable effort on the part of statisticians to improve the design and accuracy of early phase oncology trials. 

Some of this effort has been rewarded via successful implementation in actual trials, yet it would be fair to say that among clinicians, there remains some reluctance to fully embrace more efficient model-based approaches. 

One reason for such reticence is the difficulty in understanding exactly what is being offered by more modern designs.

Read J Clin Oncol article